KalGene Pharmaceuticals Inc.

KalGene Pharmaceuticals Inc. in its Series A Financing round (second tranche) of $1.67 million

Client

KalGene Pharmaceuticals Inc.

Value

$1.67 million

Service

Emerging and High Growth Companies

Date Closed

March 2018

Industry

Venture Capital

Lead Office

Montréal


 

On March 29, 2018, KalGene Pharmaceuticals Inc. announced that it had completed its second tranche of Series A financing, raising $1.67 million. The round was led by Merck Lumira Biosciences Fund, L.P. and Merck Lumira Biosciences Fund (Québec), L.P.  

KalGene Pharmaceuticals is a Canadian biotechnology company. It plans to use the funding to support the development of its leading therapeutic medicine for the treatment of Alzheimer’s disease.

Osler, Hoskin & Harcourt LLP represented KalGene Pharmaceuticals with a team consisting of Nathalie Beauregard and Tim Apedaile (Corporate).


Team